Integra LifeSciences Reports Significant FY2025 GAAP Loss Driven by $511M Impairment; Q4 Adjusted EPS Declines, Provides Modest 2026 Guidance
Summary
Integra LifeSciences reported a full-year 2025 GAAP net loss of $(516.5) million, primarily due to a $511 million goodwill impairment charge. Q4 2025 revenues and adjusted EPS declined, and the company provided modest 2026 guidance with weak Q1 projections.
Key Events
-
Full-Year 2025 GAAP Net Loss Driven by Massive Impairment
The company reported a GAAP net loss of $(516.5) million for the full year 2025, primarily due to a $511 million goodwill impairment charge recorded in the second quarter, a significant re-evaluation of asset values.
-
Q4 2025 Financial Performance Declined
Fourth quarter 2025 reported revenues decreased 1.7% to $434.9 million (2.5% organic decline), and adjusted diluted earnings per share fell to $0.83 from $0.97 in the prior year quarter.
-
Weak 2026 Financial Guidance Issued
For full-year 2026, the company expects revenues of $1,662 million to $1,702 million (1.6%-4.1% reported growth) and adjusted EPS of $2.30-$2.40. Q1 2026 guidance is weaker, projecting potential negative organic growth and lower adjusted EPS.
-
Significant Deterioration in Cash Flow and Increased Debt
Cash flow from operations for full-year 2025 significantly decreased to $50.4 million from $129.4 million in 2024, and net debt increased to $1.6 billion from $1.535 billion.
Analysis
Integra LifeSciences reported a substantial GAAP net loss of $(516.5) million for the full year 2025, primarily due to a $511 million goodwill impairment charge recorded in the second quarter. This impairment, representing over 50% of the company's market capitalization, signals a significant re-evaluation of the company's asset values and future prospects, stemming from external factors like tariffs and internal quality and supply issues. Fourth quarter 2025 results also showed declines, with reported revenues down 1.7% and adjusted diluted EPS falling to $0.83 from $0.97 year-over-year. Full-year adjusted EPS also decreased to $2.23 from $2.56. Cash flow from operations significantly deteriorated, dropping to $50.4 million in 2025 from $129.4 million in 2024, while net debt increased to $1.6 billion. The company's 2026 guidance projects modest full-year revenue growth and adjusted EPS, but the first quarter 2026 guidance indicates potential for negative organic growth and lower adjusted EPS, reflecting ongoing challenges despite reported operational progress in quality systems and remediation efforts. The overall financial performance and outlook are concerning, particularly the magnitude of the goodwill impairment and the decline in cash generation.
At the time of this filing, IART was trading at $11.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $902.8M. The 52-week trading range was $10.60 to $25.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.